Fewer older women with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer are undergoing routine sentinel lymph node biopsy (SLNB), according to data that were presented at the ...
The absolute difference in 5-year regional-recurrence free survival was 2.35% between patients who received breast conserving therapy with and without SLNB, meeting the primary endpoint for ...
The 3-year axillary RFS rate was 99.2% with axillary lymph node dissection and 98.8% with less-invasive procedures. Less-invasive lymph node procedures are noninferior to axillary lymph node ...
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...
To investigate this further, first author, Gabriella N. Tortorello, MD, and a research team from the University of Pennsylvania, performed a retrospective cohort study with data from the National ...
Omitting sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer undergoing breast-conserving surgery may not increase the risk for recurrence over 5 years, according to findings ...
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...
SAN ANTONIO – Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional ...
Purpose To reduce false-negative rates (FNR) in sentinel lymph node biopsy (SLNB) of clinically positive (cN+) axilla in patients undergoing neoadjuvant chemotherapy (NAC). The removal of three or ...
Sentinel lymph node biopsy alone noninferior with respect to disease-free survival, linked to fewer complications. HealthDay News — For patients with early-stage cervical cancer, sentinel lymph node ...
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results